Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a yearlong campaign to stop independent labs from producing cheaper versions. Former Novo Nordisk CEO ...
Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, ...
Digbi Health, the leader in precision biology for metabolic and digestive health, today announced a major expansion of its GLP-1 Compass(TM) platform with the launch of Digbi RxFund(TM). This industry ...
This experimental pill helped people lose about 16% of their body weight after about a year of treatment ...
For in-store pharmacy chains, the rise of weight-loss drugs represents a business opportunity to reshape shopping habits.
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...
Let's dive in.
In addition to their weight loss benefits, GLP-1 RAs also act on neural circuits involved in appetite, impulse control, and ...
GLP-1 medications like Ozempic, Wegovy and Mounjaro have become something of a cultural lightning rod over the past few years ...
Among patients with cancer, brain metastases, and type 2 diabetes, GLP-1 use is associated with lower all-cause mortality, ...
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use ...
Cynthia Bailey feels like the best version of herself after losing 36 pounds with a GLP-1. “It’s been a year and I was 206 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results